Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Watson Files FDA Application for Generic LoSeasonique(R)- Paragraph IV Litigation Underway

By Pharmaceutical Processing | January 8, 2010

Watson Pharmaceuticals,Inc., a specialty pharmaceutical company, today confirmedthat its subsidiary, Watson Laboratories, Inc., has filed an Abbreviated NewDrug Application (ANDA) with the U.S. Food and Drug Administration (FDA)seeking approval to market its levonorgestrel and ethinyl estradiol (0.10mg/0.02 mg) oral contraceptive product prior to the expiration of U.S. PatentNo. 7,615,545, which is owned by Duramed Pharmaceuticals, Inc., a subsidiaryof Teva Pharmaceutical Industries, Ltd. Watson’s levonorgestrel and ethinylestradiol product is a generic version of Teva’s LoSeasonique. On November 23, 2009, pursuant to the Hatch-Waxman Act, Watson notifiedDuramed that its ANDA requesting approval from the FDA for a generic versionof LoSeasonique contained a paragraph IV certification asserting that theLoSeasonique patent is invalid, unenforceable and/or not infringed. TevaWomen’s Health, Inc. filed suit against Watson on January 6, 2010 in the U.S.District Court for the District of New Jersey seeking to prevent Watson fromcommercializing its product prior to the expiration of U.S. Patent No.7,615,545. Based on available information, Watson believes it may be entitledto 180 days of generic market exclusivity or shared exclusivity should itsproduct receive approval. LoSeasonique is indicated for the prevention of pregnancy.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE